What cardiac change is associated with Zofran?

Zofran, or ondansetron, is a medication commonly used as an antiemetic to prevent nausea and vomiting, especially in patients undergoing chemotherapy or surgical procedures. One of the cardiac changes associated with Zofran is QT prolongation.

QT prolongation refers to an extended interval on an electrocardiogram (ECG) that represents the time it takes for the heart to recharge between beats. This is significant because prolonged QT can increase the risk of developing life-threatening arrhythmias like Torsades de Pointes. Ondansetron can lead to an increase in the QT interval, which is particularly concerning in patients with other risk factors for cardiac arrhythmias.

Monitoring patients for QT interval changes is essential when administering this drug, especially those with pre-existing heart conditions, electrolyte imbalances, or those taking additional medications that may also prolong the QT interval. Understanding this potential effect is crucial for ensuring patient safety in both preoperative and postoperative settings.